Chemotherapy-induced nausea and vomiting (CINV) is a common side-effect of many cancer treatments. Nausea and vomiting are two of the most feared cancer treatment-related side effects for cancer patients and their families. In 1983, Coates et al. found that patients receiving chemotherapy ranked nausea and vomiting as the first and second most severe side effects, respectively. Up to 20% of patients receiving highly emetogenic agents in this era postponed, or even refused, potentially curative treatments.

Since the 1990s, several novel classes of antiemetics have been developed and commercialized, becoming a nearly universal standard in chemotherapy regimens and helping to better manage these symptoms in a large portion of patients. Efficient mediation of these unpleasant and sometimes crippling symptoms results in increased quality of life for the patient, and better overall health of the patient, and due to better patient tolerance, more effective treatment cycles.

Affecting 70-80% of patients undergoing chemotherapy, chemotherapy-induced nausea and vomiting (CINV) is one of chemotherapy's most debilitating side effects, often attributed as a leading cause of premature discontinuation of cancer treatment.

Reports and Market Value –

The Chemotherapy Induced Nausea and Vomiting market report provides current treatment practices, emerging drugs, market share of the individual therapies, as well as current and forecasted market size from 2019 to 2032 segmented by 7 major markets. The report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

The report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. The study gives a thorough understanding by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the study provides the diagnosed patient pool and their trends along with assumptions undertaken.

The Drug chapter segment of the report encloses the detailed analysis of the marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

The research provides the details of the emerging therapies under the late and mid-stage of development for Chemotherapy Induced Nausea and Vomiting treatment. This segment gives a thorough detail of the market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

The Global Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs market was valued at US$2431.4 million in 2021 and is projected to reach US$ 2182.5 million by 2028, at a CAGR of -1.5% during the forecast period. The key players of the market include Heron Therapeutics, Merck, Eisai, Mundipharma, Qilu Pharma, Teva, Novartis, Roche, Mylan, Baxter, GSK, Helsinn, Southwest Pharma, Haisco and Sun Pharma.

Moreover, the evaluation also benefits in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions. It provides insights into different therapeutic candidates in Phase II, and Phase III stage.

In the coming years, Chemotherapy Induced Nausea and Vomiting market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market. The companies and academics are working to assess challenges and seek opportunities that could influence Chemotherapy Induced Nausea and Vomiting R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.

With the involvement of major players in developing therapies for Chemotherapy Induced Nausea and Vomiting, the launch of emerging therapies will significantly impact the market. A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics.